ProCE Banner Activity

CME

CAR T-Cell Therapy: Applying the Data, Tailoring Treatment, and Future Considerations

In this interactive on-demand Webcast, an expert panel discusses how they currently use CAR T-cells to treat hematologic malignancies and provides a look ahead at new data and promising agents that may soon change practice.

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: August 14, 2020

Expiration: August 13, 2021

No longer available for credit.

Share

Faculty

Michael R. Bishop

Michael R. Bishop, MD

Professor of Medicine, Director
Section of Hematology/Oncology,
Cellular Therapy Program
University of Chicago
Chicago, Illinois

Daniel J. DeAngelo

Daniel J. DeAngelo, MD, PhD

Chief, Division of Leukemia
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Noopur Raje

Noopur Raje, MD

Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Celgene

Legend Biotech USA Inc.

Target Audience

This program is intended for physicians and other healthcare providers who treat and manage patients with leukemia, lymphoma, or myeloma who are candidates for CAR T-cell therapies.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Review the biologic principles underlying CAR T-cell therapy, structure and function of the CAR, and the mechanism of action of CAR T-cells
  • Identify characteristics of patients that are appropriate for treatment with CAR T-cell therapy
  • Review the clinical trial data on CAR T-cell–based therapies for the treatment of patients with leukemia and lymphoma, and describe where CAR T-cell therapies might fit into the treatment landscape
  • Evaluate emerging clinical data and novel approaches to CAR T-cell therapy for patients with myeloma
  • Based on the current best evidence, implement strategies for managing toxicities associated with CAR T-cell therapy
  • Recall ongoing clinical trials evaluating CAR T-cell therapy for the treatment of leukemia, lymphoma, and myeloma to aid in the referral of appropriate patients

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director Disclosure

Program Director

Michael R. Bishop, MD

Professor of Medicine, Director
Section of Hematology/Oncology,
Cellular Therapy Program
University of Chicago
Chicago, Illinois

Michael R. Bishop, MD, has disclosed that he has received honoraria from Agios, Celgene, Gilead Sciences/Kite, OptumHealth, Pharmacyclics, and Sanofi; has served on speaker bureaus for Agios, Celgene, Gilead Sciences/Kite, Pharmacyclics, and Sanofi; and has received consulting fees from CRISPR Therapeutics, Gilead Sciences/Kite, Juno, Novartis, and OptumHealth.

Faculty Disclosure

Primary Author

Daniel J. DeAngelo, MD, PhD

Chief, Division of Leukemia
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Daniel J. DeAngelo, MD, PhD, has disclosed that he has received consulting fees from Amgen, Autolus, Axios, Blueprint, Forty Seven, Incyte, Jazz, Novartis, Servier, and Takeda and funds for research support from AbbVie, Blueprint, GlycoMimetics, and Novartis.

Noopur Raje, MD

Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Noopur Raje, MD, has disclosed that she has received consulting fees from Amgen, Bristol-Myers Squibb, Caribou, Celgene, Immuneel, Janssen, Karyopharm, and Takeda and funds for research support from Bluebird Bio.

Staff Disclosure

Staff

Jason J. Everly, PharmD

Jason Everly, PharmD, has no relevant conflicts of interest to report.

Kiran Mir-Hudgeons, PhD

Clinical Editor

Kiran D. Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Ryan P. Topping, PhD

Associate Managing Editor

Ryan P. Topping, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 14, 2020, through August 13, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge of physicians and other healthcare providers of CAR T-cell therapies so they can confidently and competently integrate these treatments into their clinical practices.